TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03719313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Lonafarnib
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lonafarnib
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ritonavir
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ritonavir
Description: Placebo
Study: NCT00259090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrazole
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Description: oral tablet
Study: NCT01589757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low GI diet
Description: Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate.
Study: NCT01436812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zero end-expiratory pressure
Description: positive end expiratory pressure 0 cm H2O during peumoperitoneum

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: positive end expiratory pressure
Description: PEEP 0 cmH2O
Study: NCT02319005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revusiran (ALN-TTRSC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Study: NCT01194947

Intervention type: DEVICE
Intervention: RCM imaging
Description: RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
Study: NCT00641095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: concentrate for solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Film coated tablet
Study: NCT03435471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Swallowing Home Exercise Program
Description: The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician-Directed Prophylactic Swallowing Exercises
Description: Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
Study: NCT03547895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)
Description: sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
Description: symptomatic therapy for liver support, control of ascites and bleeding tendency.
Study: NCT04493671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 10mg
Description: TBAJ-876 10mg tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 25mg
Description: TBAJ-876 25mg tablets,oral suspension, orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 50mg
Description: TBAJ-876 50mg tablets,oral suspension, orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 100mg
Description: TBAJ-876 100mg tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 200mg
Description: TBAJ-876 200mg tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 400mg
Description: TBAJ-876 400mg tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 Dose XXXmg for Food cohort
Description: Based on exposure levels from initial cohorts, a dose will be chosen for the food-effect cohort.
Study: NCT02465372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CSPAP
Description: Comprehensive School Physical Activity Program.
Study: NCT00281346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Description: Echocardiography
Study: NCT04493671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 XXXmg for Part 2
Description: Part 2, Multiple ascending dose (MAD) cohorts doses to be determined.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 XXXmg for Part 2
Description: Part 2, Multiple ascending dose (MAD) cohorts doses to be determined.
Study: NCT02113033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equilia® Vagal Nerve Stimulation
Description: Vagal Nerve Stimulation synchronized with cardiac activity
Study: NCT04493671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-876 XXXmg for Part 2
Description: Part 2, Multiple ascending dose (MAD) cohorts doses to be determined.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered
Study: NCT03637478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Systems of Care Team
Description: E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
Study: NCT04493671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered
Study: NCT04583332

Intervention type: OTHER
Group type: OTHER
Intervention: Rhymes
Description: Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects.

Intervention type: OTHER
Group type: OTHER
Intervention: Individual Items in Rhymes
Description: Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects.

Intervention type: OTHER
Group type: OTHER
Intervention: Objects
Description: Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
Study: NCT03165916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard 5 Fr diameter feeding tube
Description: A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
Study: NCT04493671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for TBAJ-876 tablet
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered
Study: NCT00545714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
Study: NCT04152889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
Study: NCT01702246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg, orally, once daily for 3 months
Study: NCT04504383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-943
Description: Administered by the oral route BID for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-943
Description: Administered by the oral route BID for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by the oral route BID for 12 weeks.
Study: NCT02438748

Intervention type: DEVICE
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.
Study: NCT02189421

Intervention type: DEVICE
Group type: OTHER
Intervention: ultra-slim upper endoscope
Description: Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
Study: NCT03321669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy
Description: Ingestion of capsule endoscopy for the diagnosis of small bowel lesions

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Capsule endoscopy
Description: Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
Study: NCT00966238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX125
Description: STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
Study: NCT00524446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk-containing fortified spread
Description: Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy-containing fortified spread
Description: Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maize-soy flour
Description: Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
Study: NCT05920434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomized controlled study
Description: randomized controlled study,no drugs or devices were administered to the participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomized controlled study
Description: randomized controlled study,no drugs or devices were administered to the participants.
Study: NCT04372602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: -For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Peripheral blood draw
Description: * First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: -Provided by Verastem
Study: NCT01438320

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Bioflavonoid
Study: NCT01505127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study: NCT02739191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO, Smith & Nephew
Description: Direct application of negative pressure wound therapy following Foot and Ankle surgery
Study: NCT04464681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M201-A Injection
Description: Active Substance: M201-A Route of administration: continuous intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: M201-A Placebo Route of administration: continuous intravenous injection
Study: NCT03463889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI in combination with PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET in combination with MRI
Study: NCT02235376

Intervention type: OTHER
Intervention: weaning trial of mechanical ventilation
Study: NCT02474095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Acupoint Electrical Stimulation
Description: Undergo ALTENS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Acupoint Electrical Stimulation
Description: Undergo ALTENS
Study: NCT02073279

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Satralizumab
Description: Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Study: NCT02151526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LentiGlobin BB305 Drug Product
Description: LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
Study: NCT00283933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study: NCT02889640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAGA Innovations
Description: An intensive math tutoring program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAGA Innovations
Description: An intensive math tutoring program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scale-up tutors
Description: Tutors who have been selected for hire via the one in three-and-a-half randomization process

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Tutors
Description: Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
Study: NCT02946060

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audiobooks
Description: iPods with audiobooks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tempo-pace synchronized playlists
Description: Playlists with or without RAS

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: iPods containing either a silent track or white noise
Study: NCT02421133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional care program.
Description: During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.~The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.~During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit.

Intervention type: OTHER
Group type: OTHER
Intervention: standard care program
Description: The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician...) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
Study: NCT03414346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusively ice pack
Description: Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack added 10% of water
Description: Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack added 100% of water
Description: Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.